Literature DB >> 33025339

Predictive factors of truncation artifacts in the arterial phase of Gd-EOB-DTPA-enhanced MRI: a nationwide multicenter study.

Masakatsu Tsurusaki1, Keitaro Sofue2, Hiromitsu Onishi3, Satoshi Goshima4, Atsushi Higaki5, Hiroyoshi Isoda6, Hiroki Haradome7, Kazunari Ishii8, Takamichi Murakami2.   

Abstract

PURPOSE: To identify predictive factors for truncation artifacts (TAs) in the arterial phase of Gd-EOB-DTPA-enhanced MRI in a multicenter study in Japan.
MATERIALS AND METHODS: Data on patient factors (age, sex, weight, presence of viral hepatitis, and other conditions) and imaging parameters (e.g., triggering, voxel size, matrix, k-space ordering, acquisition time, reduction factor, flip angle, fat suppression, field strength, injection rate, and saline volume) were obtained. Univariate and multivariate analyses were performed to investigate the correlation of these parameters.
RESULTS: We evaluated 1444 patients from 43 institutions who were scanned using GE, Siemens, Philips, or Toshiba MRI equipment (501, 354, 349, and 240 patients, respectively). The total incidence of TAs was 12.5% (17.2, 3.6, 15.7, and 12.1%, respectively). The matrix [odds ratio (OR) 0.13], flip angle (OR 5.77), use of fat suppression (OR 0.106), and field strength (OR 0.092) used in the Philips equipment significantly increased the incidence of TAs in MRI examination.
CONCLUSIONS: The incidence of TAs in the arterial phase is influenced by several patient factors and imaging parameters. Especially, Siemens and Toshiba equipment had a significantly lower frequency of TAs. This indicates that such vendor-specific technology used in the dynamic sequence may have a TA-resistant effect.

Entities:  

Keywords:  Contrast agent; Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid; Magnetic resonance imaging; Truncation artifact

Mesh:

Substances:

Year:  2020        PMID: 33025339     DOI: 10.1007/s11604-020-01052-x

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  18 in total

Review 1.  Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis.

Authors:  Kathryn J Fowler; Jeffrey J Brown; Vamsi R Narra
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

2.  LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions.

Authors:  Donald G Mitchell; Jordi Bruix; Morris Sherman; Claude B Sirlin
Journal:  Hepatology       Date:  2014-12-12       Impact factor: 17.425

3.  Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition.

Authors:  Jason A Pietryga; Lauren M B Burke; Daniele Marin; Tracy A Jaffe; Mustafa R Bashir
Journal:  Radiology       Date:  2014-01-21       Impact factor: 11.105

4.  Relationship between the degree of abdominal wall movement and the image quality of contrast-enhanced MRI: semi-quantitative study especially focused on the occurrence of transient severe motion artifact.

Authors:  Hiroshi Ikeno; Satoshi Kobayashi; Kazuto Kozaka; Takahiro Ogi; Dai Inoue; Norihide Yoneda; Kotaro Yoshida; Naoki Ohno; Toshifumi Gabata; Azusa Kitao
Journal:  Jpn J Radiol       Date:  2019-11-05       Impact factor: 2.374

5.  Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine.

Authors:  Matthew S Davenport; Elaine M Caoili; Ravi K Kaza; Hero K Hussain
Journal:  Radiology       Date:  2014-03-08       Impact factor: 11.105

Review 6.  2017 Version of LI-RADS for CT and MR Imaging: An Update.

Authors:  Khaled M Elsayes; Jonathan C Hooker; Michelle M Agrons; Ania Z Kielar; An Tang; Kathryn J Fowler; Victoria Chernyak; Mustafa R Bashir; Yuko Kono; Richard K Do; Donald G Mitchell; Aya Kamaya; Elizabeth M Hecht; Claude B Sirlin
Journal:  Radiographics       Date:  2017 Nov-Dec       Impact factor: 5.333

7.  Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma?

Authors:  Masatoshi Kudo
Journal:  Oncology       Date:  2010-07-08       Impact factor: 2.935

Review 8.  Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Authors:  An Tang; Mustafa R Bashir; Michael T Corwin; Irene Cruite; Christoph F Dietrich; Richard K G Do; Eric C Ehman; Kathryn J Fowler; Hero K Hussain; Reena C Jha; Adib R Karam; Adrija Mamidipalli; Robert M Marks; Donald G Mitchell; Tara A Morgan; Michael A Ohliger; Amol Shah; Kim-Nhien Vu; Claude B Sirlin
Journal:  Radiology       Date:  2017-11-21       Impact factor: 11.105

9.  Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy-A Systematic Review.

Authors:  Christian B van der Pol; Christopher S Lim; Claude B Sirlin; Trevor A McGrath; Jean-Paul Salameh; Mustafa R Bashir; An Tang; Amit G Singal; Andreu F Costa; Kathryn Fowler; Matthew D F McInnes
Journal:  Gastroenterology       Date:  2018-11-13       Impact factor: 22.682

10.  Respiratory motion artifact affecting hepatic arterial phase MR imaging with gadoxetate disodium is more common in patients with a prior episode of arterial phase motion associated with gadoxetate disodium.

Authors:  Mustafa R Bashir; Patricia Castelli; Matthew S Davenport; Douglas Larson; Daniele Marin; Hero K Hussain; Tracy A Jaffe
Journal:  Radiology       Date:  2014-08-25       Impact factor: 11.105

View more
  1 in total

1.  Influence of dilution on arterial-phase artifacts and signal intensity on gadoxetic acid-enhanced liver MRI.

Authors:  Sarah Poetter-Lang; Gregor O Dovjak; Alina Messner; Raphael Ambros; Stephan H Polanec; Pascal A T Baltzer; Antonia Kristic; Alexander Herold; Jacqueline C Hodge; Michael Weber; Nina Bastati; Ahmed Ba-Ssalamah
Journal:  Eur Radiol       Date:  2022-07-27       Impact factor: 7.034

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.